Social Prescribing Intervention for Health Promotion in Community-Dwelling Older Adults
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55+
SponsorNational Health Research Institutes, Taiwan
About this trial
This study evaluates the effects of a social prescribing intervention on health promotion outcomes in community-dwelling older adults. The intervention consists of a 4-week mindfulness meditation program followed by a 12-week walking-pole exercise program. The purpose of the study is to determine whether this combined intervention improves physical function, psychological well-being, and sleep quality.
Eligible participants aged 55 years and older will be enrolled from community settings and will receive the same 16-week intervention. Assessments will be conducted at baseline, after the mindfulness phase, after completion of the full intervention, and 3 months after the intervention ends. Study outcomes include physical function, mood, well-being, sleep quality, and indicators of continued participation and lifestyle change.
The investigators hypothesize that the combined social prescribing intervention will lead to improvements in physical and psychological health among community-dwelling older adults and support healthy aging.
Eligibility criteria
Qualifiers
Adults aged 55 years and older
Community-dwelling older adults
Able to walk independently or with assistive devices
Normal cognitive function or mild cognitive impairment, with ability to understand and follow study procedures
Disqualifiers
Major surgery or hospitalization within the previous 3 months
Severe cardiovascular disease or other medical condition making exercise inappropriate, based on physician assessment
Moderate to severe dementia or other severe psychiatric disorder
Inability to comply with the 4-week mindfulness meditation program or the 12-week walking-pole exercise program
Trial design
Treatments tested in this trial
- Mindfulness Meditation and Walking-Pole Exercise
Treatment groups
1,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov